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Impact of antibacterials on subsequent
resistance and clinical outcomes in adult
patients with viral pneumonia: an
opportunity for stewardship
Matthew P. Crotty1, Shelby Meyers2, Nicholas Hampton3, Stephanie Bledsoe4, David J. Ritchie1,2, Richard S. Buller4,
Gregory A. Storch4, Marin H. Kollef5 and Scott T. Micek2*
Abstract
Introduction: Respiratory viruses are increasingly recognized as significant etiologies of pneumonia among
hospitalized patients. Advanced technologies using multiplex molecular assays and polymerase-chain reaction
increase the ability to identify viral pathogens and may ultimately impact antibacterial use.
Method: This was a single-center retrospective cohort study to evaluate the impact of antibacterials in viral
pneumonia on clinical outcomes and subsequent multidrug-resistant organism (MDRO) infections/colonization.
Patients admitted from March 2013 to November 2014 with positive respiratory viral panels (RVP) and radiographic
findings of pneumonia were included. Patients transferred from an outside hospital or not still hospitalized 72 hours
after the RVP report date were excluded. Patients were categorized based on exposure to systemic antibacterials:
less than 3 days representing short-course therapy and 3 to 10 days being long-course therapy.
Results: A total of 174 patients (long-course, n = 67; short-course, n = 28; mixed bacterial-viral infection, n = 79) were
included with most being immunocompromised (56.3 %) with active malignancy the primary etiology (69.4 %).
Rhinovirus/Enterovirus (23 %), Influenza (19 %), and Parainfluenza (15.5 %) were the viruses most commonly identified.
A total of 13 different systemic antibacterials were used as empiric therapy in the 95 patients with pure viral infection
for a total of 466 days-of-therapy. Vancomycin (50.7 %), cefepime (40.3 %), azithromycin (40.3 %), meropenem (23.9 %),
and linezolid (20.9 %) were most frequently used. In-hospital mortality did not differ between patients with viral
pneumonia in the short-course and long-course groups. Subsequent infection/colonization with a MDRO was more
frequent in the long-course group compared to the short-course group (53.2 vs 21.1 %; P = 0.027).
Conclusion: This study found that long-course antibacterial use in the setting of viral pneumonia had no impact on
clinical outcomes but increased the incidence of subsequent MDRO infection/colonization.
Introduction
Interactions between viral and bacterial respiratory path-
ogens have been recognized dating back to the 1918
influenza pandemic [1]. Bacterial pneumonia is a well-
recognized serious complication of influenza infections
and coinfections are commonplace [2–10]. Respiratory
syncytial virus (RSV), parainfluenza viruses, rhinoviruses,
and adenoviruses have also been linked to bacterial coin-
fections in humans [11–18]. Animal studies have sug-
gested synergism between bacterial pathogens and other
respiratory viruses [19, 20]. The relationship between
viral and bacterial respiratory infections creates a diffi-
cult situation for clinicians determining the appropriate
use of antimicrobials as they treat hospitalized patients
with pneumonia while also trying to minimize the devel-
opment and selection of resistant organisms.
Respiratory viruses are increasingly recognized as the
primary etiology of pneumonia among patients requiring
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hospitalization (2.7–5 % of pneumonia cases) [21, 22].
Advanced technologies using multiplex molecular assays
and PCR improve the diagnostic ability to identify viral
pathogens in a timely manner and may impact the use
of antibacterials in patients with no bacterial infection
identified.
Several studies have investigated the impact of respira-
tory viral pathogen identification on antibacterial expos-
ure [23–26]. Decreased antibiotic use was observed in
two pediatric studies assessing the impact of rapid viral
diagnostic tests for respiratory tract infections; however,
these results were not mirrored in similar adult studies
[23–25]. These studies all used immunofluorescent
staining as the primary diagnostic technology. To our
knowledge, only one study using PCR-based respiratory
virus detection has been reported and found no change
in antibacterial use with improved diagnoses for lower
respiratory tract infections [26].
Broad-spectrum antibacterial exposure increases the
risk of subsequent infections with multidrug-resistant
organisms (MDROs) and leads to a vicious cycle of em-
piric broad-spectrum antibacterials to combat increas-
ingly resistant organisms [27]. We and others have
previously shown that patients with culture-negative
pneumonia frequently receive treatment with broad-
spectrum antibiotics, usually in excess of 5–6 days of
therapy despite lack of evidence for a bacterial etiology
of infection [28, 29]. It is important to recognize that
these studies were performed prior to the availability of
rapid viral diagnostics which may have influenced how
antibiotics were used during those study periods. Use of
new diagnostic technologies for respiratory virus detec-
tion could decrease unnecessary antibacterial exposures
and subsequent MDRO infections. This study aimed to
describe the use of continued empiric antibacterials in
patients with known viral pneumonia and to determine
the impact of such therapies on subsequent bacterial in-
fections/colonization and clinical outcomes.
Methods
This was a single-center, retrospective cohort study of
patients with a positive respiratory virus panel (RVP) at
Barnes-Jewish Hospital (BJH) (a 1300-bed urban aca-
demic medical center in St. Louis, MO, USA) between 1
March 2013 and 7 November 2014. The study protocol
was approved by the BJH, Washington University, and
St. Louis College of Pharmacy Institutional Review
Boards.
Study population
Consecutive patients who were ≥19 years of age and ad-
mitted to BJH for ≥24 hours were assessed for study inclu-
sion. Patients were identified through a query of an
internal database which tracks respiratory viruses. Patient
admissions in which a respiratory virus was identified by
FilmArray® respiratory panel (FARP) assay (BioFire Diag-
nostics, Salt Lake City, UT, USA) were screened for inclu-
sion in this study. Included patients had to meet the study
definition of viral pneumonia. Patient admissions were ex-
cluded if rhinovirus or enterovirus was identified by naso-
pharyngeal (NP) swab alone but could also be included if
identified from lower respiratory tract specimens. Add-
itionally, patients were excluded if there was a virus identi-
fied by RVP within the previous 90 days or if a bacterial
pathogen was identified by the respiratory panel. Patients
who were transferred from an outside hospital and those
who were discharged/died or were made comfort care less
than 72 hours after the index RVP report date were also
excluded to better evaluate continued empiric antibacter-
ial use in this population.
Respiratory virus panel
The FARP assay is a multiplexed nucleic acid test cap-
able of simultaneous qualitative detection and identifica-
tion of multiple respiratory viral and bacterial nucleic
acids. The FARP became the primary diagnostic RVP
used at BJH in March 2013 for all patients presenting to
the hospital with a clinical syndrome consistent with
pneumonia, as well as for patients developing a hospital-
acquired pneumonia where a viral etiology was a clinical
consideration. The FARP is capable of detecting 20 total
respiratory pathogens (17 viral and three bacterial):
Bordetella pertussis, Chlamydophila pneumoniae, Myco-
plasma pneumoniae, adenovirus, coronavirus HKU1,
coronavirus NL63, coronavirus 229E, coronavirus OC43,
influenza A, influenza A subtype H1, influenza A sub-
type H3, influenza A subtype 2009 H1, influenza B,
human metapneumovirus, parainfluenza 1, parainfluenza
2, parainfluenza 3, parainfluenza 4, RSV, and rhinovirus/
enterovirus. The FARP assay cannot reliably differentiate
between human rhinovirus and enterovirus due to their
genetic similarity. The assay is US Food and Drug
Administration-approved for NP swabs, and additional
sample types have been validated internally.
Definitions
Viral pneumonia was defined as identification of a re-
spiratory virus by FARP and a new or progressive radio-
graphic infiltrate within 48 hours of the index RVP.
Short-course antibacterial administration was defined as
treatment with systemic antibacterials for less than 3
days while long-course therapy was defined as 3–10 days
of antibiotics after the index RVP report date with no
bacterial infection identified at any point during the
admission. MDROs were defined as methicillin-resistant
Staphylococcus aureus (MRSA), vancomycin-resistant
enterococci (VRE), or a bacterium exhibiting in vitro
resistance to at least one drug in ≥3 classes of
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antibacterials for which the organism is not intrinsically
resistant [30]. Subsequent isolation of a MDRO was de-
fined as isolation of a study-defined MDRO or a positive
epidemiologic screen (MRSA NP swab; VRE stool speci-
men) ≥10 days after the report date of the index RVP.
Positive epidemiologic screens for MRSA or VRE were
only considered to be subsequent colonization of an
MDRO if the patient had at least one screen in the pre-
vious 180 days and all screening tests were negative
prior to the index RVP. Immunocompromised status
was defined as a diagnosis of human immunodeficiency
virus (HIV), active malignancy (stem cell transplant or
receiving chemotherapy), solid organ transplant, or cur-
rently on immunosuppressive therapy (prednisone 20
mg/day for at least 30 days or equivalent).
Microbiologic evaluation
Information regarding the FARP including time of col-
lection/report, type of specimen, patient location at time
of collection, and resulting findings were obtained from
an internal database. Additionally, all available aerobic
and anaerobic bacterial cultures were evaluated based on
electronic medical record (EMR) query. In vitro suscep-
tibilities of isolated bacterial pathogens were evaluated
as reported per institutional practices. Urine Legionella
antigen, direct-fluorescent antibody for Pneumocystis jir-
oveci, and Clostridium difficile toxin assay were also
evaluated.
Patient characteristics and antibacterial exposure
Data collected to describe patient groups included
demographic information, comorbid conditions, and
clinical outcomes. Charlson’s comorbidity index was
used as a summative score of underlying disease states
[31]. Antibacterial exposures were calculated using EMR
orders for systemic antibacterials. Days of therapy
(DOT) and DOT normalized per 1000 patient-days
(DOT/1000PD) were calculated as described previously
[32]. EMR queries were used to acquire patient informa-
tion where possible. Manual chart review was used to
validate and supplement all EMR queries.
Endpoints
The primary endpoint was subsequent isolation of a
MDRO ≥10 days after the index RVP report date. In-
hospital mortality and readmission at 30, 90, and 180
days were secondary endpoints.
Statistical analysis
Dichotomous variables were compared using the chi-
square test or Fisher’s exact test as appropriate. Continu-
ous variables were compared using the Mann–Whitney
U test. All tests were two-tailed and P <0.05 was consid-
ered significant. Univariate analyses were performed to
compare the group that received long-course antibacte-
rials and the group that received short-course antibacter-
ial therapy. Kaplan–Meier survival analysis was used to
compare risk of in-hospital mortality between compara-
tor groups while censoring for patient discharge. All
statistical analyses were performed using SPSS software
(IBM SPSS Statistics, version 22.0; Chicago, IL, USA).
Results
Cohort description
A total of 174 consecutive patients (long course, n = 67;
short course, n = 28; mixed bacterial–viral infection, n = 79)
were included in this study (Fig. 1). Demographic and clin-
ical characteristics are summarized in Table 1. The median
age was 57 years and 46.0 % were male. A majority of pa-
tients in the cohort were deemed to be immunocomprom-
ised (56.3 %), with active malignancy the most common
etiology (69.4 %). Only 5 of 174 patients had been admitted
within the 90 days prior to the index admission. Figure 2
provides a breakdown of the subgroup of patients screened
in the emergency department setting according to the pres-
ence of pure viral and mixed infections.
Rhinovirus/enterovirus (23.0 %), influenza (19.0 %),
and parainfluenza (15.5 %) were the viruses most com-
monly identified in the cohort (Table 2). Of the total 174
patients, 11 had multiple respiratory viruses identified by
RVP: RSV (5 of 11), rhinovirus/enterovirus (5 of 11), in-
fluenza (4 of 11), human metapneumovirus (3 of 11),
parainfluenza (2 of 11), coronavirus (2 of 11), and
adenovirus (2 of 11). Specimens resulting positive for a
respiratory virus in the cohort included NP swabs (40.8
%), bronchoalveolar lavage (25.9 %), tracheal aspirates
(18.4 %), bronchial washes (9.8 %), and sputum samples
(4.0 %). The RVP identified a respiratory virus from mul-
tiple specimens in 25 patients. Among the 25 patients
with multiple positive specimens, the most common
were bronchoalveolar lavage (19 of 25 patients) and tra-
cheal aspirates (13 of 25 patients).
Patient group characteristics
No significant differences in comorbidities between
groups were identified (Table 1). Patients with mixed
viral–bacterial infection had statistically greater APA-
CHE II scores and were more likely to require vasopres-
sor support compared with patients with pure viral
infection. There was no significant difference in the
number of immunocompromised patients between
groups, although numerically more patients who re-
ceived long-course antibacterials had an active malig-
nancy or solid organ transplant compared with patients
receiving short-course therapy. Virus types identified by
FARP assay were similar in all three patient groups
(Table 2). The bacterial coinfecting organisms identified
in patients with mixed viral–bacterial infection are
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presented in Table 3. Respiratory coinfection with a
bacterial pathogen was most common, with S. aureus,
Streptococcus pneumoniae, and Pseudomonas aeruginosa
accounting for the most frequent respiratory coinfecting
bacteria.
Antibacterial use
A total of 13 different systemic antibacterials were used
as empiric treatment in patients with viral pneumonia
without bacterial coinfection for a total of 466 DOT.
Vancomycin (50.7 %), cefepime (40.3 %), azithromycin
(40.3 %), meropenem (23.9 %), and linezolid (20.9 %)
were the most frequently used empiric antibacterials in
patients with viral pneumonia without bacterial coinfec-
tion (Fig. 3). The most common regimens used in viral
pneumonia without bacterial coinfection were vanco-
mycin plus cefepime (28.4 %) and vancomycin plus mer-
openem (13.4 %). A total of 44 (65.7 %) patients with
viral pneumonia without bacterial coinfection received
empiric MRSA coverage with vancomycin or linezolid.
Empiric antibacterial therapy was continued for a me-
dian of 4.1 days (interquartile range, 2.5–6.1 days) in
viral pneumonia without bacterial coinfection, with most
(69 %) being days on intravenous antibacterials.
Total antibacterial exposure differed between the long-
course and short-course groups at 2116 and 484 DOT/
1000PD, respectively (Fig. 3). Patients with mixed viral
and bacterial infections received a total of 780 DOT/
1000PD of systemic antibacterials. Median total antibac-
terial DOT/1000PD was also significantly higher in the
long-course group compared with the short-course group
(12.2 vs. 6.4; P <0.001) and the mixed-infection group
(12.2 vs. 6.3; P <0.001). The most common antibacterials
used were similar between groups: cefepime (long-course
group: 73.1 %; short-course group: 50 %; mixed-infection
group: 58.2 %), meropenem (long-course group: 37.3 %;
short-course group: 32.1 %; mixed-infection group: 43.0
%), and linezolid (long-course group; 31.3 %; short-course
group: 25 %; mixed-infection group: 41.7 %). Vancomycin
was more commonly used in the long-course group
compared with the mixed-infection group (80.6 vs.
59.5 %; P = 0.007) but not compared with the short-
course group (80.6 vs. 57.1 %; P = 0.081). Azithromy-
cin use was less prevalent in the mixed-infection
group compared with the long-course group (48.1 %
vs. 67.2 % of patients; P = 0.029) and the short-course
group (48.1 vs. 71.4 %; P = 0.047).
Clinical outcomes
The number of patients with subsequent MDRO
colonization or infection was not significantly different be-
tween groups (Table 4). However, in instances of subse-
quent infection or colonization, where a single patient
could have more than one organism, there was a higher
rate of MDRO identification among isolates from the
group that received long-course antibacterials compared
with the group receiving short-course therapy (53.2 vs.
21.1 %; P = 0.027) (Table 4). VRE (35 %), coagulase-
negative Staphylococcus sp. (15 %), Escherichia coli (10 %),
Enterobacter cloacae (10 %), and Stenotrophomonas
Fig. 1 Identification of study population. Short-course antibacterial group did not receive empiric antibacterials from RVP+3 to RVP+10, long-course
antibacterial group received empiric antibacterials between RVP+3 and RVP+10, and mixed viral–bacterial infection group included patients with both
identification of a respiratory virus and a bacterial pathogen. NP nasopharyngeal, R/E rhinovirus/enterovirus, RVP respiratory virus panel, RVP+3 3 days
after index RVP, RVP+10 10 days after index RVP
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maltophilia (10 %) were the most commonly isolated
MDROs in the long-course group. Other MDROs isolated
from this group included Klebsiella pneumoniae, Serratia
marcescens, S. pneumoniae, and Achromobacter sp. The
three subsequent infecting MDROs in the short-course
group were VRE, E. cloacae, and Corynebacterium sp.
One patient in the long-course group and two patients in
the mixed-infection group developed C. difficile infection
1 week after empiric antibacterial exposure.
In-hospital mortality was statistically higher for the
mixed-infection group compared with the long-course
therapy group (Table 4). Kaplan–Meier survival analysis
showed that the mixed-infection group had the lowest
overall survival, but these differences were not statistically
Table 1 Demographic and clinical characteristics of patients with viral pneumonia according to empiric antibacterial therapy
Long course Short course Mixed infection
(n = 67) (n = 28) (n = 79)
Age 55 (45–66) 57.5 (45–65) 56 (45–69)
Male 33 (49.3) 15 (53.6) 32 (40.5)
Caucasian 43 (64.2) 17 (60.7) 45 (57.0)
African American 20 (29.9) 7 (25) 30 (38.0)
Weight (kg) 81.3 (65.5–95.3) 74.3 (67.5–104.2) 73.5 (55.1–88.7)*
BMI 27.6 (22.6–35.1) 27.3 (22.7–33.8) 25.8 (20.1–32.0)*
Prior admit within 90 days 2 (3.0) 0 (0) 3 (3.8)
Chronic heart failure 12 (17.9) 6 (21.4) 12 (15.2)
Coronary artery disease 13 (19.4) 4 (14.3) 15 (19.0)
COPD 12 (17.9) 9 (32.1) 16 (20.3)
Diabetes mellitus 25 (37.3) 8 (28.6) 25 (31.6)
Chronic kidney disease 15 (22.4) 5 (17.9) 21 (26.6)
ESRD on hemodialysis 6 (9.0) 0 (0) 7 (8.9)
Cirrhosis 2 (3.0) 0 (0) 1 (1.3)
Human immunodeficiency virus 1 (1.5) 0 (0) 2 (2.5)
Active malignancy 31 (46.3) 11 (39.3) 26 (33.0)
Stem cell transplant 14 (20.9) 5 (17.9) 10 (12.7)
Solid organ transplant 9 (13.4) 2 (7.1) 9 (11.4)
Lung 4 (6.0) 2 (7.1) 8 (10.1)
Heart 2 (3.0) 0 (0) 1 (1.3)
Kidney 3 (4.5) 0 (0) 0 (0)
Immunosuppressive therapy 1 (1.5) 3 (10.7) 8 (10.1)*
Immunocompromised 39 (58.2) 15 (53.6) 44 (55.7)
CCI 4 (3–6) 3 (1–5) 4 (2–6)
Intensive care unit admit 44 (65.7) 17 (60.7) 63 (79.7)
Oncologya 18 (26.9) 5 (17.9) 16 (20.3)
Nononcology 26 (38.8) 12 (42.9) 47 (59.5)*
Mechanical ventilation 34 (50.7) 10 (35.7) 53 (67.1)**
Days 5.9 (3.4–13.7) 3.7 (1.85–27.2) 7.0 (3.3–11.9)*
Central line placed 56 (83.6) 14 (50) 53 (67.1)*
Vasopressor support 14 (20.9) 4 (14.3) 35 (44.3)*,**
Days 3.55 (1.93–13.1) 2.2 (0.8–10.6) 6.3 (3.4–11.6)
APACHE II score 15 (11–20) 14 (8–17) 19 (14–23)*,**
Data expressed as number (% of total) or median (interquartile range)
aICU admit was determined to be oncology related if the patient fit the study definition for active malignancy
*Statistically significant difference (P <0.05) between long-course and mixed-infection groups
**Statistically significant difference (P <0.05) between short-course and mixed-infection groups
BMI body mass index, CCI Charlson’s comorbidity index, COPD chronic obstructive pulmonary disease, ESRD end-stage renal disease
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significant (Fig. 4). ICU mortality was also significantly
higher for patients in the mixed-infection group compared
with the long-course therapy group. Patients receiving
long-course therapy or those with mixed infection had
statistically longer ICU length of stay compared with
patients receiving short-course therapy. Hospital readmis-
sion rates were similar between groups at 30, 90, and 180
days after index hospitalization discharge.
Discussion
This study compared a cohort of 174 patients with viral
pneumonia and mixed viral–bacterial infection based on
exposure to continued empiric antibacterials after re-
spiratory virus identification. More of the subsequent in-
fecting or colonizing bacterial isolates from the group
with pure viral pneumonia who received continued
long-course antibacterials were defined as MDROs com-
pared with the short-course group (P = 0.027). These
findings suggest that more prolonged exposure to
broad-spectrum antibacterials in patients with viral
pneumonia may have promoted resistance in these
patients.
No benefit of continued empiric antibacterials for pa-
tients with pure viral pneumonia was seen in this study.
The risk of bacterial coinfection in the setting of viral
pneumonia, especially with influenza, creates a challen-
ging situation for clinicians. The potential detrimental
impact of not treating a bacterial pathogen weighs
Fig. 2 Patients with pure viral pneumonia or mixed viral–bacterial infection as screened in the emergency department. Pure viral pneumonia
group included patients with identification of a respiratory virus only. Mixed viral–bacterial infection group included patients with both
identification of a respiratory virus and bacterial pathogen. NP nasopharyngeal, R/E rhinovirus/enterovirus, RVP respiratory virus panel
Table 2 Viruses identified by FA RP in patients with viral
pneumonia according to empiric antibacterial therapy
Long course Short course Mixed infection
(n = 67) (n = 28) (n = 79)
Rhinovirus/enterovirus 15 (22.4) 6 (21.4) 19 (24.1)
Influenza 14 (20.9) 4 (14.3) 15 (19.0)
Parainfluenza 12 (17.9) 7 (25) 8 (10.1)
Respiratory syncytial virus 8 (11.9) 3 (10.7) 8 (10.1)
Human metapneumovirus 8 (11.9) 3 (10.7) 6 (7.6)
Coronavirus 6 (9.0) 2 (7.1) 8 (10.1)
Adenovirus 3 (4.5) 1 (3.6) 7 (8.9)
Multiple viruses 1 (1.5) 2 (7.1) 8 (10.1)
Data expressed as number (% of total)
No statistically significant differences were found between groups
Table 3 Coinfecting bacterial organisms identified in patients
with viral pneumonia
Mixed infection
(n = 79)
Corespiratory infection 52 (65.8)
Staphylococcus aureus 25 (31.6)
MSSA 12 (15.2)
MRSA 19 (24.1)
Streptococci 10 (12.7)
Streptococcus pneumoniae 9 (11.4)
Pseudomonas aeruginosa 8 (10.1)
Enterobacteriaceae 5 (6.3)
Urinary tract infection 17 (21.5)
Enterococci 8 (10.1)
Enterobacteriaceae 8 (10.1)
P. aeruginosa 1 (1.3)
Skin and skin structure infection 8 (10.1)
Intra-abdominal infection 2 (2.5)
Data expressed as number (% of total)
MRSA methicillin-resistant Staphylococcus aureus, MSSA methicillin-susceptible
Staphylococcus aureus
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Fig. 3 Total antibacterial use among patients with viral pneumonia according to empiric antibacterial therapy groups and mixed infection. DOT/
1000PD days of therapy normalized per 1000 patient-days
Table 4 Clinical outcomes of patients with viral pneumonia according to empiric antibacterial therapy
Long course Short course Mixed infection
(n = 67) (n = 28) (n = 79)
Instances of subsequent MDRO infection or colonization 25/47 (53.2) 4/19 (21.1)* 20/53 (37.7)
MRSA colonization 2/10 (20) 0/7 (0) 3/15 (20)
VRE colonization 3/6 (50) 1/4 (25) 9/20 (45)
MDRO infection 20/31 (64.5) 3/8 (37.5) 8/18 (44.4)
Patients with subsequent MDRO infection or colonization 16 (23.9) 3 (10.7) 16 (20.3)
MRSA colonization 2 (3.0) 0 (0) 3 (3.8)
VRE colonization 3 (4.5) 1 (3.6) 9 (11.4)
MDRO infection 13 (19.4) 3 (10.7) 7 (8.9)
Subsequent Clostridium difficile infection 1 (1.5) 0 (0) 2 (2.5)
In-hospital mortality 8 (11.9) 3 (10.7) 23 (29.1)**
Non-ICU 1/23 (4.3) 0/11 (0) 0/16 (0)
ICU (all) 7/44 (15.9) 3/17 (17.6) 23/63 (36.5)**
ICU – oncology 4/18 (22.2) 2/5 (40) 10/16 (62.5)**
ICU – nononcology 3/26 (11.5) 1/12 (8.3) 13/47 (27.7)
Hospital LOS (days) 11 (7–25) 8.5 (5–20) 17 (8.5-28) ***
ICU LOS (days) 8.1 (4.9-17.9) 4.2 (2.8-14.7)* 12 (5.1-19.1) ***
Readmit within
30 days 14 (20.9) 4 (12.9) 19 (24.0)
90 days 22 (32.8) 8 (25.8) 27 (48.2)
180 days 30 (44.8) 11 (35.5) 29 (51.8)
Data expressed as number (% of total) or median (interquartile range)
LOS length of stay, MDRO multidrug-resistant organism, MRSA methicillin-resistant Staphylococcus aureus, VRE vancomycin-resistant enterococci
*Statistically significant difference (P <0.05) between short-course and long-course groups
**Statistically significant difference (P <0.05) between long-course and mixed-infection groups
***Statistically significant difference (P <0.05) between short-course and mixed-infection groups
Crotty et al. Critical Care  (2015) 19:404 Page 7 of 11
heavily on the decision process and downstream effects
of such therapies may be disregarded. Our findings of
similar clinical outcomes between patients with pure
viral pneumonia who received long-course antibacterials
after virus recognition and those who did not may sug-
gest opportunity for de-escalation of empiric antibacter-
ial therapy when viral pneumonia is identified.
A previous randomized controlled trial by Oosterheert
et al. [26] evaluated implementation of real-time PCR
rapid diagnostics for respiratory pathogen identification.
They found increased diagnostic yield with the assay but
no difference in antibiotic use, and hypothesized that re-
luctance to change treatment based on testing results
may have inhibited cost-effectiveness from being demon-
strated. In our study, systemic antibacterials were dis-
continued following identification of a respiratory virus
by RVP for several patients; however, whether virus
identification directly led to discontinuation of antibac-
terials cannot be determined. The willingness of pre-
scribers to de-escalate and stop antibacterials in this
setting may suggest increased recognition of the role of
viral pathogens in pneumonia. Additionally, the ex-
panded panel of viruses detected may have factored into
how results were perceived, as prescribers may have
been more likely to attribute pneumonia to newly de-
tectable viruses such as human metapneumovirus. How-
ever, it is not possible to definitively determine the
rationale for stopping antibacterial therapy.
Timely antibiotic administration is crucial for treating
hospitalized patients with suspected pneumonia [33].
Antimicrobial de-escalation attempts to balance the use
of these essential drugs up front with the emergence of
resistance [34]. The optimal strategy for de-escalation of
antibacterials in the setting of viral pneumonia without
an identified bacterial coinfection is unclear. Our study
found no difference in clinical outcomes based on anti-
biotic duration of therapy in patients with viral pneumo-
nia despite significantly different total antibacterial
exposure (DOT/1000PD) between groups. Byington et
al. [24] found previously that improved diagnostic tech-
nologies enhancing detection of respiratory viruses de-
creased antibacterial use at a children’s hospital. The
authors concluded that improved diagnostics are an im-
portant tool in decreasing unnecessary antibacterial pre-
scribing. Our study similarly illustrated the potential
impact of respiratory virus diagnostics on antibacterial
use in an adult population.
C. difficile infection is a major cause of morbidity and
mortality in US hospitals and has been directly linked to
exposure to broad-spectrum antibiotics [35, 36]. In a co-
hort of hospitalized adult patients, Shiley et al. [37]
found that significantly more patients who continued to
receive antibacterials after diagnosis of a viral respiratory
tract infection developed C. difficile infection. One pa-
tient in our study who was treated with long-course an-
tibacterials after identification of a respiratory virus also
developed C. difficile infection. Strategies to best limit
the use of unneeded antibacterials are important to cur-
tail against the growing issues of C. difficile and resist-
ance, and may be aided by de-escalation approaches
using enhanced viral diagnostic technologies.
Limitations of this study should be noted. First, this
was a small retrospective cohort study of patients at a
single institution and may not be representative of all
settings. It is important to note that BJH is a regional
specialty referral hospital and not a community hospital.
This accounts for the case mix with a high prevalence of
immunosuppressed patients and the low prevalence of
Fig. 4 Kaplan–Meier survival analysis among patients with viral pneumonia according to antibacterial treatment course and mixed viral–bacterial
infection. Log-rank test: short course versus long course, P = 0.854; short course versus mixed infection, P = 0.349; long course versus mixed infection,
P = 0.152. RVP +3 = 3 days after index respiratory viral panel
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narrow spectrum empiric antibiotic utilization. The
small number of patients meeting inclusion criteria did
not allow for definitive conclusions to be made regard-
ing group comparison as a lack of statistically significant
differences being found could be due to the lack of sam-
ple size. Second, patients were determined to have viral
pneumonia based on virus identification and radio-
graphic findings but other markers of illness, such as
white blood cell count and fever, were not considered
and the retrospective nature of the study did not allow
evaluation of what drove continuation of antibacterials
in some patients but not others. Moreover, we did not
attempt to identify risk factors associated with pure viral
pneumonia. Third, although coinfecting bacterial patho-
gens were not identified in patients with pure viral pneu-
monia, it is impossible to prove that they were not
present. Receipt of antibacterials prior to obtaining bac-
terial cultures could have limited the diagnostic yield of
bacterial cultures in some cases and yield from bacterial
cultures is not perfect. Finally, all of the viral pneumonia
cases occurred in a 20-month period. Viral epidemiology
during this time may not be representative of all seasons.
Influenza H1N1 p2009 was the primary influenza virus
identified in our study (85 %). Incidence rates of bacter-
ial coinfection and coinfecting organisms may differ
from year to year and from virus type to virus type,
which may hinder application of de-escalation strategies
using the results of this study.
It is not possible to directly link the development of sub-
sequent MDRO infections/colonization and C. difficile
infection seen in our study to the continued empiric anti-
bacterials administered. All of the patients included in the
cohort received antibacterials at some point during their
index hospitalization and infection control measures were
not directly assessed in these patients. Additionally,
hospitalization itself probably increases the risk of these
patients being colonized with MDROs. Use of cephalospo-
rins and vancomycin, two of the most commonly adminis-
tered empiric agents in our study, have been implicated as
increasing the prevalence of VRE, the most commonly
identified subsequent MDRO in this study [38, 39]. De-
creasing exposure to broad-spectrum antibacterials such
as third-generation and fourth-generation cephalosporins
and vancomycin would be expected to lessen the inci-
dence of VRE and other MDROs as was seen in this study,
but the risk of development and transmission of resistance
in the hospital cannot be completely eliminated. Antibac-
terials are extraordinarily important in the treatment of
many hospitalized patients and their use is often war-
ranted. Decreasing unnecessary use may help curb ac-
quirement of resistant organism in healthcare settings but
even appropriate use can lead to the development of re-
sistance. Only through multifaceted efforts of infection
control and antimicrobial stewardship can the spread of
MDROs between patients, clinicians, workers, and visitors
be diminished.
Conclusions
This study highlights the potential benefits of improved
diagnostics for respiratory viruses, primarily the poten-
tial for decreased antibacterial exposure and thus de-
creased selective pressure for resistant bacterial isolates.
Antibacterial exposure applies selective pressure and
promotes colonization/infection by resistant organisms
including MRSA and VRE [40, 41]. Halting this process
is essential to maintain effective therapeutic options in
the future and may be aided by discontinuation of anti-
bacterials in cases of viral pneumonia. In our study, pa-
tients with viral pneumonia exposed to long-course
antibacterials had more occurrences of subsequent infec-
tion or colonization with MDRO isolates. In contrast,
the number of patients with subsequent MDRO infec-
tion or colonization was not different between groups al-
though this may be due to the small number of patients
in each group. No differences in clinical outcomes, in-
cluding in-hospital mortality and readmission rates, were
observed between patient groups. In the setting of viral
pneumonia and no coinfecting bacterial pathogens, dis-
continuation of antibacterials is reasonable in many if
not most cases, and may allow for decreased overall
antibacterial use. Enhanced diagnostic technologies can
potentially be incorporated into antimicrobial steward-
ship practices to allow for de-escalation of unnecessary
antibacterials. These findings warrant further investiga-
tion to determine the applicability of an antibacterial de-
escalation approach in the setting of viral pneumonia.
Key messages
 In this single-center retrospective cohort, patients with
viral pneumonia who continued to be treated with
systemic antibacterials 3 days after virus identification
were more likely to have a subsequent infection or
colonization with a MDRO than were patients in
whom systemic antibacterials were stopped.
 In-hospital mortality based on Kaplan–Meier
survival analysis and readmission rates were not
different between groups based on antibacterial
exposure after respiratory virus identification.
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